30 closest matches · ranked by relevance
COVID · Severe Acute Respiratory Syndrome · Sars-CoV2
Primary: To Evaluate the Proportion of Subjects Alive and Free of Respiratory Failure and Free of the Need for Continued Renal Replacement Therapy (RRT) on Day 28 (as Per…
Survival Status at Day 30 After the Last Intake
Primary: Percentage of Participants With Survival at 30 Days After Last Dose of Tigecycline — 80.60 percentage of participants
Palliative Medicine · Cardiovascular Disease
Primary: Proportion of Deaths Within 60 Days of Enrollment. — 0.203; 0.238 proportion of deaths
Myelodysplastic Syndrome
Primary: Participants Survival Status as of the Time of the Extension Study Follow-up — 101; 29; 18 participants
Critically Ill
Primary: Documented Infection Rate — 58; 41 Infections
Herpes Zoster
Primary: Frequencies of Glycoprotein E (gE)-Specific Cluster of Differentiation 4 (CD4) / CD8 T Cells With at Least Two Antigen-specific Cytokines: Interferon Gamma (IFN-γ)…
Acute Alcoholic Hepatitis
Primary: Overall Survival — 57; 66 Participants — p=0.904
Neuroendocrine Tumors · Hepatic Metastases · Metastases
Primary: Rate of Hepatic Progression Free Survival at 24 Months — 47; 20 Participants
Brain Death
Primary: Primary Outcome Measure is IL-6 Level — 565.5; 264.9 pg/ml
Healthy
Primary: Serum Glutamic Oxaloacetic Transaminase (AST/SGOT) — 21.48 U/L
Acute Stress Ulcer and Acute Gastric Mucosal Lesions
Primary: Number of Participants Reporting One or More Adverse Drug Reactions — 0 participants
Healthy
Primary: Change in Live LcS Numbers From Baseline (Day 14) to the End of the Ingestion Period (Day 28). — 2.14; 5.27 Log 10 CFU/g Feces
COVID-19
Primary: Time to Recovery for Participants With Baseline Ordinal Score 4, 5 and 6 — 5.0; 5.0 Days — p=0.880
Effect of Individualized Nutrition on Quality of Life
Primary: Global Quality of Life Score — 58.8; 55.4 units on a scale
Post-Resuscitation Syndrome · Critical Illness · Cardiac Arrest
Primary: 30-Day Mortality — 112 participants
Acute Respiratory Failure · Shock
Primary: Mortality — 422; 443 Participants
Breast Cancer · Prostate Cancer · Lung Cancer
Primary: IGF-1 Levels — 73.2; 73.6; 71.2 ng/ml
Breast Augmentation
Primary: To Evaluate if the Subject Has Macrolane Deposits in the Breast Seven Years Post Treatment, Using a Comprehensive MRI Investigation — 4 participants with remaining product
Diffuse Large B-cell Lymphoma
Primary: Overall Response Rate — 29.3 percentage of participants
Haematological Malignancy
Primary: The Between-group Change for Body Weight — -4.0; -3.4 kilogram — p=0.24
Healthy
Primary: Post Infusion Recovery of Test Platelets at End of Storage (Day 7) — 39.5; 57.8; 39.1; 60.4 percentage of infused platelets
COVID-19
Primary: The Proportion of Participants Not Meeting Criteria for One of the Following Two Ordinal Scale Categories at Any Time: 8) Death; 7) Hospitalized, on Invasive Mechanical…
Diabetes Mellitus, Type 2 · Obesity · Gastroparesis
Primary: Presence of RGV (Residual Gastric Volume) in Stomach — 7; 1 Participants
Binge Eating Disorder
Primary: Time to Relapse From Date of Randomization to Endpoint of The Randomized-withdrawal Period — NA; NA days — p=<0.001
Health Behavior
Primary: Stool Frequency — 2.2; 2.2; 2.3; 1.6 Times per day
Chronic Graft-versus-host-disease
Primary: Duration of Response (DOR) — NA; NA months
Glioma · Astrocytoma · Oligodendroglioma
Primary: Percentage of Participants Surviving at Six Months of Treatment Without Evidence of Disease Progression. — 35.7; 27.3; 7.4; 35.7 Percentage of Participants
Acute Respiratory Distress Syndrome · Vitamin D Deficiency · Critical Illness
Primary: All-cause, All-location Mortality to Day 90 — 125; 109 Participants — p=0.26
Breast Feeding · Breast Feeding, Exclusive
Primary: Exclusive Breastfeeding on the Day Preceding the Interview as Assessed by Cross Sectional Survey — 0.933; 0.512 percentage of exclusive breastfeeding
Multiple Trauma
Primary: Death — 52 participants — p=< 0.001